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March 21, 2006:1226–38hours of ischemia: effects on infarct size, ventricular function, and
regional myocardial blood flow. Am Heart J 1990;120:808–18.
. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of
intracoronary adenosine as an adjunct to primary angioplasty in acute
myocardial infarction. Circulation 2000;101:2154–9.
MISTAD Trials: Possible
easons for Lack of Success
esults of the Acute Myocardial Infarction STudy of ADenosine
AMISTAD II) trial were recently reported by Ross et al. (1). As
n the AMISTAD I trial (2), most of the conclusions were at best
quivocal, although subgroup analysis each time suggested aden-
sine might be useful as an adjunct to reperfusion therapy in
ertain patients with acute myocardial infarction. Thus the hope
as raised that a more targeted trial might yield a significant
ifference between placebo and treatment groups. Although this
ossibility is real, we would like to offer an alternative hypothesis.
ontrary to the twice-repeated assertion by the investigators that
adenosine . . . has consistently provided myocardial protection
rom ischemic injury in animal models,” the ability of adenosine
dministered at or shortly before reperfusion to provide cardiopro-
ection against infarction is indeed quite controversial. There are
ertainly some studies which report that adenosine at reperfusion
an decrease infarct size in various animal models, and some of
hese experimental investigations are acknowledged by Ross et al.
1). However, it is notable that two of the references cited by the
esearchers to justify their conclusion have been misquoted. Yao
nd Gross (3) and Thornton et al. (4) found protection when
denosine or an adenosine agonist was used as a preconditioning
gent.
Furthermore, Thornton et al. (4) actually observed that when
6-(2-phenylisopropyl) adenosine (PIA) was infused at reperfu-
ion, it had no cardioprotective effect despite its effectiveness when
pplied as a pretreatment. Also, numerous other preclinical studies
ave been unable to document an effect of authentic adenosine
5–8) at reperfusion on infarct size. Therefore, it is possible that
oth the inability to demonstrate a significant effect of adenosine
t reperfusion in patients and the inconsistent preclinical results are
ecause adenosine given at reperfusion simply does not protect the
eart.
In the two AMISTAD trials it was reported that infarct size
as significantly diminished in those patients with anterior wall
yocardial infarction who were treated with adenosine. Although
his observation is potentially important and noteworthy, a tech-
ical limitation diminishes the significance of the data. It has been
ecognized for many years that a major determinant of infarct size
s the size of the region at risk. In fact, no experimental study of
nfarct size limitation would be accepted for publication if the size
f the risk region were not quantitated and used to normalize the
easurement of infarct size. It is recognized that it is difficult, but
ot impossible, to obtain these data in clinical studies because
cans must be recorded both before and after the intervention.
eliance on absolute infarct size as a percentage of the left
entricle—despite the many reasonable correlations between this
arameter and measures of ventricular function and clinical out-
ome, without normalization for the size of the region at risk—can
ield incorrect conclusions. And this difficulty is perhaps best
ighlighted by the very different measurements of infarction in
atients treated with placebo: 45% in the AMISTAD I study and
7% in the AMISTAD II study. dMichael V. Cohen, MD
ames M. Downey, PhD
Department of Physiology
SB 3050
niversity of South Alabama
ollege of Medicine
obile, Alabama 36688
-mail: mcohen@usouthal.edu
doi:10.1016/j.jacc.2005.12.040
EFERENCES
. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A
randomized, double-blinded placebo-controlled multicenter trial of
adenosine as an adjunct to reperfusion in the treatment of actue
myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:
1775–80.
. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an
adjunct to thrombolytic therapy for actue myocardial infarction: results
of a multicenter, randomized, placebo-controlled trial: the Acute
Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am
Coll Cardiol 1999;34:1711–20.
. Yao Z, Gross GJ. A comparison of adenosine-induced cardioprotection
and ischemic preconditioning in dogs: efficacy, time course, and role of
KATP channels. Circulation 1994;89:1229–36.
. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pretreat-
ment with A1-selective adenosine analogues protects the heart against
infarction. Circulation 1992;85:659–65.
. Goto M, Miura T, Iliodoromitis EK, et al. Adenosine infusion during
early reperfusion failed to limit myocardial infarct size in a collateral
deficient species. Cardiovasc Res 1991;25:943–9.
. Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfu-
sion on myocardial infarct size in dogs. Cardiovasc Res 1996;31:711–8.
. Budde JM, Velez DA, Zhao Z-Q, et al. Comparative study of AMP579
and adenosine in inhibition of neutrophil-mediated vascular and myo-
cardial injury during 24 h of reperfusion. Cardiovasc Res 2000;47:
294–305.
. Xu Z, Downey JM, Cohen MV. AMP 579 reduces contracture and
limits infarction in rabbit heart by activating adenosine A2 receptors.
J Cardiovasc Pharmacol 2001;38:474–81.
EPLY
e thank Drs. Cohen and Downey for their interest in our report
n treatment of anterior myocardial infarction with adenosine (1).
e do not agree that we misquoted Yao and Gross (2) and
hornton et al. (3) with respect to the cardioprotective effects of
denosine. The Thornton et al. study was cited, with others, in
tating that “adenosine has consistently provided myocardial pro-
ection from ischemic injury.” The Yao and Gross study (2)
upports the statement that “adenosine and adenosine agonists are
yocardial protectants.” We did not say that this protection was
pecifically related to the time of reperfusion, as implied. The
eduction in infarct size may have been related also to other
alutary effects of adenosine. In many patients the drug was on
oard during at least part of the time of coronary occlusion, and
hus it might have a protective effect during ischemia. Certainly, in
hose receiving thrombolytic therapy, there was a time lag between
dministration of the lytic and when reperfusion was complete.
hus, it is possible that adenosine played a protective role during
his time of continuing ischemia.
We do not agree that the difference in infarct size in the
MISTAD I and AMISTAD II studies somehow imputes the
eliability of the single-photon emission computed tomography
ata in the AMISTAD II study. The validity of SPECT infarct
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March 21, 2006:1226–38ize measurement is well-established (4) on the basis of multiple
ines of scientific evidence. We agree that myocardium at risk is
ighly variable and a major determinant of infarct size in both
nimal models and humans. The absence of measurement of
yocardium at risk will reduce power (i.e., increase the likelihood
f a type II [beta] statistical error). However, the estimates
eported in our paper of a type I (alpha) statistical error for infarct
ize remain valid. In the AMISTAD I study (5), myocardium at
isk was measured in a subset of patients. In anterior infarcts,
denosine showed similar benefit using either myocardial salvage
ndex (p  0.015) or infarct size (p  0.014). Other randomized
rials that have measured myocardium at risk and infarct size (6,7)
ave reported similar significant differences using either infarct size
r salvage index as an end point.
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tatins and Antioxidant Vitamins:
hould Co-Administration Be Avoided?
n the interesting study by Arad et al. (1), co-administration of
torvastatin (20 mg/day) and high-dose antioxidant vitamins C (1 g/
ay) and E (1,000 IU/day) failed to decrease the progression of
oronary calcification, whereas a borderline decrease of cardiovas- rular events was observed. Based on the fact that previous studies
ave shown that statins do decrease both the progression of
oronary artery calcification and cardiovascular events (2), the
nvestigators proposed that the atorvastatin dosage they used was
ow, and they suggested that their population was not large enough
o detect any differences. However, another possibility might be
onsidered: The results of the present study may reflect a negative
ffect of antioxidant vitamins (especially vitamins C and E), which
ould interfere with lipoprotein metabolism, preventing the statin-
nduced increase of high-density lipoprotein (HDL)-2 subfraction,
s has been proposed in the past (3). Indeed, in a study by Brown
t al. (4), it was shown that co-administration of statin and
ntioxidant vitamins C and E partly prevents the beneficial effects
f statins on cardiovascular outcome. Additionally, we (5) have
ecently demonstrated that, although low-dose atorvastatin treat-
ent (10 mg/day) improves endothelial function in patients with
schemic heart disease, this effect is abolished when vitamin E (400
U/day) is co-administered. Therefore, further studies examining
he effect of atorvastatin 10 to 20 mg/day alone on the progression
f coronary artery calcification and clinical events rate are required
efore any conclusion is made.
Dimitris Tousoulis, MD, PhD, FACC
haralambos Antoniades, MD
hristodoulos Stefanadis, MD, FACC, FESC
Athens University Medical School
ippokration Hospital
asilissis Sophias 114
15 28 Athens
reece
-mail: tousouli@med.uoa.gr
doi:10.1016/j.jacc.2005.12.033
EFERENCES
. Arad Y, Spadaro LA, Roth M, Newstein D, Guerci AD. Treatment of
asymptomatic adults with elevated coronary calcium scores with ator-
vastatin, vitamin C, and vitamin E: the St. Francis Heart Study
Randomized Clinical Trial. J Am Coll Cardiol 2005;46:166–72.
. Achenbach S, Ropers D, Pohle H, et al. Influence of lipid-lowering
therapy on the progression of coronary artery calcification. A prospec-
tive evaluation. Circulation 2002;106:1077–82.
. Cheung M, Zhao XQ, Chait A, et al . Antioxidant supplements block
the response of HDL to simvastatin–niacin therapy in patients with
coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol
2001;21:1320–6.
. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin,
antioxidant vitamins or the combination for the prevention of coronary
disease. N Engl J Med 2001;345:1583–92.
. Tousoulis D, Antoniades C, Vasiliadou C, et al. Effects of combined
administration of low dose atorvastatin and vitamin E on inflammatory
markers and endothelial function in patients with heart failure. Eur J
Heart Fail 2005;7:1126–32.
EPLY
s Dr. Tousoulis and colleagues point out, the design of the St.
rancis Heart Study Randomized Clinical Trial (two cells of a 2
factorial) does not permit a definitive conclusion as to whether
tatins alone retard the progression of coronary calcification.
owever, there are other reasons to believe that statins do noteduce the rate of coronary calcification, or, if they do, that said
